Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex Pharmaceuticals recently announced its largest-ever acquisition.
Overview
Vertex Pharmaceuticals (NASDAQ: VRTX) has a robust business that centers around cystic fibrosis therapies. But its growth rate has been slowing down of late. And despite having a stellar pipeline and encouraging growth prospects, the stock's returns over the past year have been nominal.
Now, with the company announcing plans for a big $10 billion acquisition of Crinetics Pharmaceuticals (NASDAQ: CRNX), could that make the pharma stock a much better buy, perhaps even a no-brainer buy at its current valuation?
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.